Literature DB >> 9290376

Plasminogen in proliferative vitreoretinal disorders.

P Esser1, K Heimann, K U Bartz-Schmidt, P Walter, R Krott, M Weller.   

Abstract

OBJECTIVE: Intravitreal fibrin formation is a frequent observation after vitrectomy performed for a variety of vitreoretinal disorders including proliferative vitreoretinopathy (PVR), proliferative diabetic retinopathy (PDR), and endophthalmitis. Plasminogen activators (PA) have been used for the management of this postoperative complication. This approach requires the presence of plasminogen, the substrate for PA mediated fibrinolysis, in the vitreal cavity.
METHODS: Quantification of plasminogen in the vitreous of 60 patients with PVR, PDR, and macular pucker was performed by streptokinase mediated activation using a chromogenic substrate. The presence of immunoreactive plasminogen was confirmed by immunoblot analysis of vitreal proteins and immunocytochemistry of surgically removed epiretinal membranes.
RESULTS: Plasminogen levels were dramatically increased in the vitreous of PVR and PDR patients compared with macular pucker patients and normal controls. Staining for plasminogen in epiretinal membranes was confined to the extracellular matrix. Predominant staining of perivascular areas in PDR specimens indicated that breakdown of the blood-retinal barrier is an important source of intravitreal plasminogen in that condition.
CONCLUSION: Plasminogen may play a role in traction membrane formation in PVR and PDR. Our biochemical analysis of presurgical vitreous indicates that there may be abundant substrate for PA mediated fibrinolysis in the vitreous cavity after vitrectomy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9290376      PMCID: PMC1722258          DOI: 10.1136/bjo.81.7.590

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  40 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Treatment of experimental intravitreal fibrin with tissue plasminogen activator.

Authors:  F H Lambrou; R W Snyder; G A Williams; M Lewandowski
Journal:  Am J Ophthalmol       Date:  1987-12-15       Impact factor: 5.258

3.  Pigment epithelium proliferation in retinal detachment (massive periretinal proliferation).

Authors:  R Machemer; H Laqua
Journal:  Am J Ophthalmol       Date:  1975-07       Impact factor: 5.258

4.  Increased thromboplastic potential in diabetes: a multifactorial phenomenon.

Authors:  M M Landgraf-Leurs; T Ladik; B Smolka; T Bock; W Schramm; M Spannagl; R Landgraf
Journal:  Klin Wochenschr       Date:  1987-07-01

5.  Fifteen coagulation and fibrinolysis parameters in diabetes mellitus and in patients with vasculopathy.

Authors:  M Christe; J Fritschi; B Lämmle; T H Tran; G A Marbet; W Berger; F Duckert
Journal:  Thromb Haemost       Date:  1984-10-31       Impact factor: 5.249

6.  Reduced fibrinogen survival in diabetes mellitus. A reversible phenomenon.

Authors:  R L Jones; C M Peterson
Journal:  J Clin Invest       Date:  1979-03       Impact factor: 14.808

Review 7.  Basics and practice in evaluating plasminogen.

Authors:  H Vinazzer
Journal:  Haemostasis       Date:  1988

Review 8.  Plasminogen: a brief introduction into its biochemistry and function.

Authors:  C Miyashita; E Wenzel; M Heiden
Journal:  Haemostasis       Date:  1988

9.  The significance of fibronectin in vitreoretinal pathology. A critical evaluation.

Authors:  M Weller; P Wiedemann; K Heimann; K Zilles
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1988       Impact factor: 3.117

10.  S protein modulates the heparin-catalyzed inhibition of thrombin by antithrombin III. Evidence for a direct interaction of S protein with heparin.

Authors:  K T Preissner; G Müller-Berghaus
Journal:  Eur J Biochem       Date:  1986-05-02
View more
  6 in total

1.  Intracameral concentrations of the fibrinolytic system components in patients with age-related macular degeneration.

Authors:  Thomas Bertelmann; Marta Spychalska; Laura Kohlberger; Stefan Strodthoff; Michael Witteborn; Nadia Kicova; Ulrich Sachs; Sebastian Irle; Stefan Mennel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-05-12       Impact factor: 3.117

2.  Intravitreal vascular endothelial growth factor.

Authors:  Thomas Bertelmann; Stephan Schulze; Reka Bölöni; Walter Sekundo; Sebastian Irle; Thomas Stief; Stefan Mennel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-04       Impact factor: 3.117

3.  Plasminogen activators promote excitotoxicity-induced retinal damage.

Authors:  Raghuveer S Mali; Mei Cheng; Shravan K Chintala
Journal:  FASEB J       Date:  2005-08       Impact factor: 5.191

4.  Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review.

Authors:  Eric W Schneider; Mark W Johnson
Journal:  Clin Ophthalmol       Date:  2011-08-18

Review 5.  Untangling the Extracellular Matrix of Idiopathic Epiretinal Membrane: A Path Winding among Structure, Interactomics and Translational Medicine.

Authors:  Laura Bianchi; Annalisa Altera; Virginia Barone; Denise Bonente; Tommaso Bacci; Elena De Benedetto; Luca Bini; Gian Marco Tosi; Federico Galvagni; Eugenio Bertelli
Journal:  Cells       Date:  2022-08-15       Impact factor: 7.666

Review 6.  Inflammatory and Fibrogenic Factors in Proliferative Vitreoretinopathy Development.

Authors:  Rishika Chaudhary; Robert A H Scott; Graham Wallace; Martin Berry; Ann Logan; Richard J Blanch
Journal:  Transl Vis Sci Technol       Date:  2020-02-21       Impact factor: 3.283

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.